October 18, 2016
L.O.M. Medical International Inc. and L.O.M. Laboratories Inc. (“L.O.M.”) are pleased to invite you to a Corporate Shareholder Update And Information Meeting. Corporate Information meetings are being held in several cities across Canada due to the progress L.O.M. has achieved, and the importance that the Board feels in regards to all shareholders having access to current information and the opportunity to participate in the current $2 share “Rights Offering”. This is an opportunity for you and interested investors to receive a Corporate update and to personally `see a demonstration of the L.O.M. 3 ml retractable safety syringe that will soon be in production.
Herbert Towning, President and CEO, Ralph Woloschuk VP/CTO of L.O.M. along with Jeremy Webster of Deloitte Life Sciences Division will present the agenda as noted below.
To attend please R.V.S.P. by email to firstname.lastname@example.org or call Debbie Ulansky at 604-616-6265
“The Pender Room”
Located in the Oceanic Plaza Towers
1066 West Hastings Street
Vancouver BC V6E 3X2
November 3rd, 5:00 pm to 7:00pm
Summary of LOM
History of the business
Regulatory and clinical Leadership
Near term milestones
Questions & Discussion and Summary
Followed by Refreshments
October 15, 2016
L.O.M. Medical International Inc. and L.O.M. Laboratories Inc. (together “LOMMI”) have completed three significant steps toward bringing our 3 ml Retractable Safety Syringe into production and onto the market:
First: Symbient Product Development has completed production quality molds and they will soon produce a designated quantity of syringes required for US FDA and European CE certification.
Second: LOMMI has contracted CE Medical Experts to complete the FDA and CE certifications. CE Medical Experts have confirmed that the laboratories of Smithers Viscenes Ltd. (“Smithers”) in the United Kingdom will conduct the required laboratory process required for both certifications. Further, Smithers would be able to start carrying out the testing for both FDA and CE, thus reducing the time for both certifications between 3 – 4 months.
Third: LOMMI has signed an Original Equipment Manufacturer agreement with Shanghai Kindly Development Group Ltd (“KDL”). KDL is a major syringe manufacturer for a number of the largest syringe companies in the world. KDL will first build up to 20,000 3 mL syringes that LOMMI will use for pre-marketing purposes of our syringe Intellectual Property to our interested distributors.
The efforts of the Board of Directors and the Advisory Board to place shares at $7.00 and the Bridge Loan have met with limited success to date. Therefore, the Board has decided that a private placement is necessary to maintain the momentum gained by the recent developments and improve LOMMI’s financial position. Additionally, part of the proceeds of a private placement would be used to repay $900,000 of debt, which is accruing interest, thereby reducing available funds to pay for capturing the advances that have been achieved.
To this end, the Board has decided to offer an opportunity to participate in a CAD$3 million private placement (the “Private Placement”) in which current shareholders of L.O.M. Laboratories Inc. (“L.O.M. Canada”) and L.O.M. Medical International Inc. (“L.O.M. US”) will have the first right to participate in the issue of up to 1,500,000 Class B Common shares (each an “L.O.M. Canada B Share”) in L.O.M. Canada at a price at $2.00 per L.O.M. Canada B Share. The discounted price reflects in part a reward to those who have waited and supported L.O.M. Canada and L.O.M. US in the long past, while providing encouragement and benefit to shareholders to continue supporting L.O.M. Canada to achieve its objectives promptly.
The offering, subscription agreement documentation may be obtained by sending an email to
Debbie Ulansky at 604-616-6265.